Agios Pharmaceuticals Quarterly Income Statements Chart
Quarterly
|
Annual
Agios Pharmaceuticals Quarterly Income Statements Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 | 2017-06-30 | 2017-03-31 | 2016-12-31 | 2016-09-30 | 2016-06-30 | 2016-03-31 | 2015-12-31 | 2015-09-30 | 2015-06-30 | 2015-03-31 | 2014-12-31 | 2014-09-30 | 2014-06-30 | 2014-03-31 | 2013-12-31 | 2013-09-30 | 2013-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| revenues: | |||||||||||||||||||||||||||||||||||||||||||||||||
| product revenue | 12,455,000 | 8,726,000 | 10,730,000 | 8,964,000 | 8,615,000 | 8,189,000 | 7,103,000 | 7,399,000 | 6,712,000 | 5,609,000 | 4,310,000 | 3,516,000 | 3,082,000 | 832,000 | 36,909,000 | 39,118,000 | 31,716,000 | 27,581,000 | 22,674,000 | 19,564,000 | 17,422,000 | 13,727,000 | 9,138,000 | 9,376,000 | 4,465,000 | ||||||||||||||||||||||||
| total revenue | 12,455,000 | 8,726,000 | 10,730,000 | 8,964,000 | 8,615,000 | 8,189,000 | 7,103,000 | 7,399,000 | 6,712,000 | 5,609,000 | 4,310,000 | 3,516,000 | 5,582,000 | 832,000 | 41,409,000 | 44,045,000 | 34,706,000 | 37,347,000 | 87,098,000 | 35,440,000 | 26,024,000 | 26,221,000 | 30,227,000 | 30,013,000 | 15,198,000 | 40,414,000 | 8,762,000 | 9,799,000 | 11,358,000 | 6,744,000 | 6,268,000 | 6,268,000 | |||||||||||||||||
| yoy | 44.57% | 6.56% | 51.06% | 21.15% | 28.35% | 46.00% | 64.80% | 110.44% | 20.24% | 574.16% | -97.99% | -52.46% | 24.28% | 33.36% | 42.43% | 188.15% | 18.08% | 71.23% | -35.12% | 244.98% | 206.29% | 33.81% | |||||||||||||||||||||||||||
| qoq | 42.73% | -18.68% | 19.70% | 4.05% | 5.20% | 15.29% | -4.00% | 10.24% | 19.66% | 30.14% | 22.58% | -37.01% | 570.91% | -5.98% | 26.91% | -7.07% | -57.12% | 145.76% | 36.18% | -0.75% | -13.25% | 0.71% | 97.48% | -62.39% | 361.24% | -10.58% | -13.73% | 7.59% | 0.00% | ||||||||||||||||||||
| operating expenses: | |||||||||||||||||||||||||||||||||||||||||||||||||
| cost of sales | 1,702,000 | 1,085,000 | 1,260,000 | 783,000 | 1,495,000 | 627,000 | 586,000 | 633,000 | 1,108,000 | 554,000 | 413,000 | 517,000 | 435,000 | 339,000 | 706,000 | 959,000 | 638,000 | 675,000 | 533,000 | 287,000 | 393,000 | 303,000 | 334,000 | 702,000 | 695,000 | ||||||||||||||||||||||||
| gross profit | 10,753,000 | 7,641,000 | 9,470,000 | 8,181,000 | 7,120,000 | 7,562,000 | 6,517,000 | 6,766,000 | 5,604,000 | 5,055,000 | 3,897,000 | 2,999,000 | 5,147,000 | 493,000 | 40,703,000 | 43,086,000 | 34,068,000 | 36,672,000 | 86,565,000 | 35,153,000 | 25,631,000 | 25,918,000 | 29,893,000 | 29,311,000 | 14,503,000 | ||||||||||||||||||||||||
| yoy | 51.03% | 1.04% | 45.31% | 20.91% | 27.05% | 49.59% | 67.23% | 125.61% | 8.88% | 925.35% | -98.79% | -52.98% | 22.57% | 32.92% | 41.49% | 189.58% | 19.93% | 76.73% | |||||||||||||||||||||||||||||||
| qoq | 40.73% | -19.31% | 15.76% | 14.90% | -5.85% | 16.03% | -3.68% | 20.74% | 10.86% | 29.72% | 29.94% | -41.73% | 944.02% | -5.53% | 26.47% | -7.10% | -57.64% | 146.25% | 37.15% | -1.11% | -13.30% | 1.99% | 102.10% | ||||||||||||||||||||||||||
| gross margin % | 86.33% | 87.57% | 88.26% | 91.27% | 82.65% | 92.34% | 91.75% | 91.44% | 83.49% | 90.12% | 90.42% | 85.30% | 92.21% | 59.25% | 98.30% | 97.82% | 98.16% | 98.19% | 99.39% | 99.19% | 98.49% | 98.84% | 98.90% | 97.66% | 95.43% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | |||||||||||||||||
| research and development | 91,940,000 | 72,743,000 | 82,810,000 | 72,455,000 | 77,401,000 | 68,620,000 | 77,489,000 | 81,841,000 | 68,895,000 | 67,301,000 | 70,298,000 | 64,966,000 | 74,523,000 | 70,123,000 | -142,110,000 | 64,000,000 | 62,007,000 | 41,357,000 | 95,742,000 | 89,555,000 | 90,917,000 | 91,256,000 | 106,248,000 | 101,672,000 | 107,389,000 | 95,585,000 | 93,809,000 | 82,561,000 | 86,730,000 | 78,224,000 | 77,216,000 | 72,917,000 | 79,816,000 | 62,732,000 | 64,678,000 | 60,643,000 | 50,804,000 | 44,038,000 | 36,933,000 | 36,028,000 | 36,423,000 | 32,443,000 | 34,862,000 | 25,526,000 | 22,576,000 | 17,407,000 | 15,279,000 | 14,803,000 | 12,958,000 |
| selling, general and administrative | 45,869,000 | 41,527,000 | 51,697,000 | 38,537,000 | 35,536,000 | 31,014,000 | 35,305,000 | 25,822,000 | 30,409,000 | 28,367,000 | 32,771,000 | 29,123,000 | 28,264,000 | 31,515,000 | -81,366,000 | 27,152,000 | 29,215,000 | 8,131,000 | 39,778,000 | 34,840,000 | 35,951,000 | 38,501,000 | 34,834,000 | 33,019,000 | 32,390,000 | 31,791,000 | |||||||||||||||||||||||
| total operating expenses | 139,511,000 | 115,355,000 | 135,767,000 | 111,775,000 | 114,432,000 | 100,261,000 | 113,380,000 | 108,296,000 | 100,412,000 | 96,222,000 | 103,482,000 | 94,606,000 | 113,363,000 | 102,774,000 | 99,929,000 | 90,375,000 | 95,946,000 | 77,555,000 | 80,057,000 | 72,497,000 | 63,448,000 | 54,875,000 | 47,116,000 | 45,955,000 | 45,352,000 | 39,397,000 | 41,363,000 | 30,692,000 | 26,741,000 | 20,695,000 | 18,986,000 | 17,337,000 | 14,794,000 | ||||||||||||||||
| income from operations | -127,056,000 | -106,629,000 | -125,037,000 | -102,811,000 | -105,817,000 | -92,072,000 | -106,277,000 | -100,897,000 | -93,700,000 | -90,613,000 | -99,172,000 | -91,090,000 | -97,640,000 | -101,145,000 | -68,397,750 | -91,152,000 | -91,222,000 | -92,434,000 | -90,327,000 | -90,196,000 | -43,192,000 | -105,929,000 | -109,060,000 | -113,861,000 | -97,483,000 | -96,356,000 | -99,162,000 | -72,949,000 | -94,012,000 | -90,130,000 | -79,017,000 | -84,600,000 | -67,047,000 | -57,409,000 | -63,512,000 | -56,470,000 | -23,594,000 | -40,898,000 | -40,475,000 | -32,133,000 | -5,195,000 | -26,727,000 | 3,208,000 | -18,330,000 | -12,284,000 | -12,242,000 | -11,069,000 | -8,526,000 | |
| yoy | 20.07% | 15.81% | 17.65% | 1.90% | 12.93% | 1.61% | 7.16% | 10.77% | -4.04% | -10.41% | 44.99% | -0.07% | 7.04% | -26.00% | 0.91% | 1.14% | -12.74% | -17.18% | -20.78% | -55.69% | 9.94% | 9.98% | 56.08% | 3.69% | 6.91% | 25.49% | -13.77% | 40.22% | 57.00% | 24.41% | 49.81% | 184.17% | 40.37% | 56.92% | 75.74% | 354.17% | 53.02% | -1361.69% | 75.30% | -57.71% | 118.32% | -128.98% | 114.99% | ||||||
| qoq | 19.16% | -14.72% | 21.62% | -2.84% | 14.93% | -13.37% | 5.33% | 7.68% | 3.41% | -8.63% | 8.87% | -6.71% | -3.47% | 47.88% | -24.96% | -0.08% | 2.33% | 0.15% | 108.83% | -59.23% | -2.87% | -4.22% | 16.80% | 1.17% | -2.83% | 35.93% | -22.40% | 4.31% | 14.06% | -6.60% | 26.18% | 16.79% | -9.61% | 12.47% | 139.34% | -42.31% | 1.05% | 25.96% | 518.54% | -80.56% | -933.14% | -117.50% | 49.22% | 0.34% | 10.60% | 29.83% | |||
| operating margin % | -1020.12% | -1221.97% | -1165.30% | -1146.93% | -1228.29% | -1124.34% | -1496.23% | -1363.66% | -1396.01% | -1615.49% | -2300.97% | -2590.73% | -1749.19% | -12156.85% | 0% | -209.86% | -260.26% | -241.51% | -49.59% | -298.90% | -419.07% | -434.24% | -322.50% | -321.05% | -652.47% | -180.50% | -1072.95% | -919.79% | -695.69% | -181.52% | -176.60% | -136.02% | |||||||||||||||||
| interest income | 14,513,000 | 16,087,000 | 18,015,000 | 13,059,000 | 8,120,000 | 8,889,000 | 8,624,000 | 8,375,000 | 8,254,000 | 8,091,000 | 6,488,000 | 3,818,000 | 1,793,000 | 694,000 | 126,000 | 256,000 | -92,000 | 791,000 | 1,115,000 | 1,769,000 | 2,936,000 | 3,579,000 | 2,887,000 | 3,990,000 | 4,405,000 | 4,562,000 | 4,498,000 | 4,204,000 | 3,187,000 | 1,845,000 | 1,880,000 | 1,518,000 | 881,000 | 923,000 | 678,000 | 517,000 | 396,000 | 276,000 | 218,000 | 236,000 | 238,000 | 85,000 | 48,000 | 34,000 | 36,000 | 29,000 | 13,000 | 5,000 | |
| other income | 523,000 | 1,253,000 | 1,623,000 | 1,651,000 | 1,579,000 | 1,634,000 | 1,713,000 | 1,198,000 | 1,640,000 | 1,504,000 | 1,357,000 | 1,082,000 | 1,337,000 | 2,973,000 | 2,791,250 | 4,641,000 | 6,524,000 | ||||||||||||||||||||||||||||||||
| net income | -112,020,000 | -89,289,000 | -96,523,000 | 947,915,000 | -96,118,000 | -81,549,000 | -95,940,000 | -91,324,000 | -83,806,000 | -81,018,000 | 36,526,000 | -81,747,000 | -91,806,000 | -94,774,000 | 424,835,500 | -88,766,000 | -86,217,000 | -97,657,000 | -98,979,000 | -90,478,000 | -40,256,000 | -102,350,000 | -106,173,000 | -109,871,000 | -93,078,000 | -91,794,000 | -94,664,000 | -68,745,000 | -90,825,000 | -88,285,000 | -77,137,000 | -83,082,000 | -66,166,000 | -56,486,000 | -62,834,000 | -55,953,000 | -23,198,000 | -40,622,000 | -40,257,000 | -31,897,000 | -4,957,000 | -26,664,000 | 3,704,000 | -18,296,000 | -12,248,000 | -12,382,000 | -11,177,000 | -8,620,000 | |
| yoy | 16.54% | 9.49% | 0.61% | -1137.97% | 14.69% | 0.66% | -362.66% | 11.72% | -8.71% | -14.51% | -91.40% | -7.91% | 6.48% | -535.03% | -10.32% | -4.71% | -4.59% | -6.78% | -17.65% | -56.75% | 11.50% | 12.16% | 59.82% | 2.48% | 3.97% | 22.72% | -17.26% | 37.27% | 56.30% | 22.76% | 48.49% | 185.22% | 39.05% | 56.08% | 75.42% | 367.98% | 52.35% | -1186.85% | 74.34% | -59.53% | 115.34% | -133.14% | 112.25% | ||||||
| qoq | 25.46% | -7.49% | -110.18% | -1086.20% | 17.87% | -15.00% | 5.05% | 8.97% | 3.44% | -321.81% | -144.68% | -10.96% | -3.13% | -122.31% | -578.60% | 2.96% | -1.34% | 9.40% | 124.76% | -60.67% | -3.60% | -3.37% | 18.04% | 1.40% | -3.03% | 37.70% | -24.31% | 2.88% | 14.45% | -7.16% | 25.57% | 17.14% | -10.10% | 12.30% | 141.20% | -42.89% | 0.91% | 26.21% | 543.47% | -81.41% | -819.87% | -120.24% | 49.38% | -1.08% | 10.78% | 29.66% | |||
| net income margin % | -899.40% | -1023.25% | -899.56% | 10574.69% | -1115.71% | -995.84% | -1350.70% | -1234.27% | -1248.60% | -1444.43% | 847.47% | -2325.00% | -1644.68% | -11391.11% | 0% | -221.72% | -285.19% | -242.26% | -46.22% | -288.80% | -407.98% | -419.02% | -307.93% | -305.85% | -622.87% | -170.10% | -1036.58% | -900.96% | -679.14% | -183.60% | -178.32% | -137.52% | |||||||||||||||||
| net income per share | -1.93 | -1.55 | -1.72 | 16.65 | -1.69 | -1.45 | -1.72 | -1.64 | -1.51 | -1.47 | 0.67 | -1.49 | -1.68 | -1.74 | 6.798 | -1.56 | -1.41 | -1.41 | -1.43 | -1.31 | -0.59 | -1.59 | -1.81 | -1.87 | -1.59 | -1.58 | -1.63 | -1.19 | -1.63 | -1.81 | -1.59 | -1.78 | -1.56 | -1.35 | -1.63 | -1.47 | -0.61 | -1.09 | -1.07 | -0.85 | -0.13 | -0.78 | 0.11 | -0.54 | -0.39 | -0.57 | -0.47 | -2.8 | |
| weighted-average number of common shares used in computing net income per share – basic and diluted | 57,932,576 | 57,459,195 | 56,802,546 | 56,383,475 | 55,803,663 | 55,604,330 | 55,265,390 | 68,997,879 | 69,144,061 | 68,958,091 | 68,608,279 | 59,994,539 | 58,803,534 | 58,722,244 | 58,453,918 | 57,418,300 | 58,033,386 | 57,721,786 | 55,694,603 | 46,587,631 | 48,459,424 | 46,745,760 | 42,280,525 | ||||||||||||||||||||||||||
| gain on sale of contingent payments | 889,136,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| milestone payment from gain on sale of oncology business | 200,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| net income before taxes | -105,399,000 | 1,001,035,000 | |||||||||||||||||||||||||||||||||||||||||||||||
| income tax expense | -8,876,000 | 53,120,000 | -12,867,000 | ||||||||||||||||||||||||||||||||||||||||||||||
| weighted-average number of common shares used in computing net income per share – basic | 56,807,415 | 56,939,403 | |||||||||||||||||||||||||||||||||||||||||||||||
| weighted-average number of common shares used in computing net income per share – diluted | 57,889,255 | 58,432,796 | |||||||||||||||||||||||||||||||||||||||||||||||
| milestone revenue | 2,500,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| royalty income from gain on sale of oncology business | 4,443,000 | 2,704,000 | 2,704,000 | ||||||||||||||||||||||||||||||||||||||||||||||
| net income from continuing operations | 36,526,000 | -81,747,000 | -91,806,000 | -94,774,000 | -64,481,500 | -84,259,000 | -82,790,000 | ||||||||||||||||||||||||||||||||||||||||||
| net income from discontinued operations, net of tax | 489,317,000 | -4,507,000 | -3,427,000 | ||||||||||||||||||||||||||||||||||||||||||||||
| net income from continuing operations per share - basic and diluted | 0.67 | -1.49 | -1.68 | -1.74 | -1.033 | -1.48 | -1.36 | ||||||||||||||||||||||||||||||||||||||||||
| net income from discontinued operations per share - basic and diluted | 7.828 | -0.08 | -0.06 | ||||||||||||||||||||||||||||||||||||||||||||||
| weighted-average number of common shares used in computing net income per share from continuing operations, net income from discontinued operations and net income per share – basic and diluted | 54,844,579 | 54,799,680 | 54,555,467 | ||||||||||||||||||||||||||||||||||||||||||||||
| cost and expenses: | |||||||||||||||||||||||||||||||||||||||||||||||||
| total cost and expenses | 103,222,000 | 101,977,000 | -222,770,000 | 91,152,000 | 91,222,000 | 50,194,000 | 136,479,000 | 125,033,000 | 127,543,000 | 130,290,000 | 141,369,000 | 135,084,000 | 140,082,000 | 127,710,000 | 126,369,000 | 114,360,000 | |||||||||||||||||||||||||||||||||
| gain on sale of oncology business | 999,000 | 1,996,000 | 2,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||
| weighted-average number of common shares used in computing net income per share from continuing operations, net income per share from discontinued operations and net income per share – basic and diluted | 55,651,487 | 54,789,435 | 57,048,175 | 61,066,977 | |||||||||||||||||||||||||||||||||||||||||||||
| collaboration revenue – related party | 1,350,000 | 1,236,000 | 1,206,000 | 5,735,000 | 60,097,000 | 6,843,000 | 5,516,000 | 8,979,000 | 17,919,000 | 18,183,000 | 8,732,000 | 26,401,000 | 7,345,000 | 8,577,000 | 10,643,000 | 11,346,000 | 10,508,000 | 22,648,000 | 8,985,000 | 6,978,000 | 31,281,000 | 6,218,000 | 5,480,000 | 13,219,000 | 34,202,000 | 8,411,000 | |||||||||||||||||||||||
| collaboration revenue – other | 491,000 | 785,000 | 1,101,000 | 692,000 | 993,000 | 6,060,000 | 420,000 | 812,000 | 970,000 | 230,000 | 12,440,000 | ||||||||||||||||||||||||||||||||||||||
| royalty revenue – related party | 2,659,000 | 2,906,000 | 683,000 | 3,339,000 | 3,334,000 | 2,973,000 | 2,666,000 | 2,703,000 | 2,200,000 | 2,224,000 | 2,001,000 | 1,573,000 | 1,417,000 | 1,222,000 | 715,000 | ||||||||||||||||||||||||||||||||||
| income from discontinued operations | -8,785,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| non-cash interest expense for the sale of future revenue | -5,697,000 | -6,014,000 | -9,767,000 | -2,051,000 | |||||||||||||||||||||||||||||||||||||||||||||
| gain on the sale of the oncology business | 1,992,551,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| income from discontinued operations, pre-tax | 1,978,069,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| net income from discontinued operations | 1,965,202,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| sales, general and administrative | 20,571,750 | 31,104,000 | |||||||||||||||||||||||||||||||||||||||||||||||
| general and administrative | 26,633,000 | 24,550,000 | 22,713,000 | 17,458,000 | 16,130,000 | 14,823,000 | 15,379,000 | 11,854,000 | 12,644,000 | 10,837,000 | 10,183,000 | 9,927,000 | 8,929,000 | 6,954,000 | 6,501,000 | 5,166,000 | 4,165,000 | 3,288,000 | 3,707,000 | 2,534,000 | 1,836,000 | ||||||||||||||||||||||||||||
| weighted-average number of common shares used in net income per share – basic and diluted | 39,126,400 | 38,548,153 | 37,956,383 | 37,864,084 | 37,329,220 | 37,214,747 | |||||||||||||||||||||||||||||||||||||||||||
| income before benefit for income taxes | -19,277,500 | -40,257,000 | -26,642,000 | 3,256,000 | -12,213,000 | -11,056,000 | -8,521,000 | ||||||||||||||||||||||||||||||||||||||||||
| benefit for income taxes | 22,000 | -448,000 | 169,000 | 121,000 | 99,000 | ||||||||||||||||||||||||||||||||||||||||||||
| weighted-average number of common shares used in net income per share – basic | 37,507,298 | ||||||||||||||||||||||||||||||||||||||||||||||||
| weighted-average number of common shares used in net income per share – diluted | 37,507,298 | ||||||||||||||||||||||||||||||||||||||||||||||||
| gross collaboration revenue – related party | 12,680,500 | 33,900,000 | |||||||||||||||||||||||||||||||||||||||||||||||
| cumulative preferred stock dividends | -8,324,000 | 567,000 | -1,798,000 | ||||||||||||||||||||||||||||||||||||||||||||||
| net income applicable to common stockholders | -26,664,000 | 3,704,000 | -18,296,000 | -12,248,000 | -20,706,000 | -10,610,000 | -10,418,000 | ||||||||||||||||||||||||||||||||||||||||||
| weighted-average number of common shares used in net income per share applicable to common stockholders – basic | 34,495,076 | ||||||||||||||||||||||||||||||||||||||||||||||||
| weighted-average number of common shares used in net income per share applicable to common stockholders – diluted | 36,592,683 | ||||||||||||||||||||||||||||||||||||||||||||||||
| income before benefit from income taxes | -18,296,000 | -12,248,000 | |||||||||||||||||||||||||||||||||||||||||||||||
| benefit from income taxes | |||||||||||||||||||||||||||||||||||||||||||||||||
| weighted-average number of common shares used in net income per share applicable to common stockholders – basic and diluted | 37,429,262 | 33,667,024 | 33,602,472 | 31,394,563 | 15,415,373 | 22,744,486 | 3,722,963 | ||||||||||||||||||||||||||||||||||||||||||
| collaboration revenue—related party | 8,411,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
| collaboration revenue | 6,744,000 | 6,268,000 | 6,268,000 | ||||||||||||||||||||||||||||||||||||||||||||||
| grant revenue |
We provide you with 20 years income statements for Agios Pharmaceuticals stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Agios Pharmaceuticals stock. Explore the full financial landscape of Agios Pharmaceuticals stock with our expertly curated income statements.
The information provided in this report about Agios Pharmaceuticals stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.